Contact Us
If you have a question about a medical condition, consult with a healthcare professional or, in the case of an emergency, call 911 immediately.
Standard business hours for CSL Behring are 8:30 am to 5:00 pm Eastern time.
| CSL Behring Headquarters |
| Phone: |
610-878-4000 |
| Fax: |
610-878-4009 |
| Location: |
North America Headquarters |
| Address: |
P.O. Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA |
|
|
| Consumer Affairs |
| For Consumer Information |
| Phone: |
888-508-6978 |
| Fax: |
610-878-4008 |
| |
| Medical Affairs |
| Phone: |
800-504-5434 |
| Fax: |
610-878-4007 |
| |
| Adverse Events |
| Phone: |
610-878-4193 |
| Phone (After Business Hours): 866-915-6958 |
|
All fields marked with an asterisk (*) are required.
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.
Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.